5-(Thiophen-3-yl)isoxazole-3-carboxylic acid | 1243662-42-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(Thiophen-3-yl)isoxazole-3-carboxylic acid
• 英文别名: 5-thiophen-3-yl-1,2-oxazole-3-carboxylic acid
• CAS: 1243662-42-1
• 化学式: C₈H₅NO₃S
• mdl: MFCD22573429
• 分子量: 195.2
• InChiKey: MJIFKVKUYBJCCP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  91.6
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Isoxazole Derivatives and Use Thereof
  申请人：Cho Jeong Woo

  公开号：US20090131336A1

  公开（公告）日：2009-05-21

  Disclosed herein are isoxazole derivaties and uses thereof. Serving as agonists of Wnt, the isoxazole derivatives activate Wnt/β-catenin signaling and thus can be used in the treatment and prevention of diseases related to the signal transduction. Also, pharmaceutically acceptable salts of the isoxazole derivatives are disclosed.

  本文披露了异噁唑衍生物及其用途。作为Wnt的激动剂，异噁唑衍生物激活Wnt/β-连环蛋白信号传导，因此可用于治疗和预防与信号传导相关的疾病。此外，还披露了异噁唑衍生物的药用盐。
• 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF
  申请人：Chung Coo-Min

  公开号：US20140128427A1

  公开（公告）日：2014-05-08

  Provided are a novel derivative of 5-carbamoyl adamantan-2-yl amide or a pharmaceutically acceptable salt thereof, and a pharmaceutical use thereof for inhibiting the activity of 11β-hydroxystreroid dehydrogenase type 1 (11b-HSD1) or for preventing and/or treating various diseases mediated by 11β-hydroxystreroid dehydrogenase type 1.

  提供了一种新型的5-氨基甲酰基亚当替烷-2-基酰胺衍生物或其药学上可接受的盐，并且其在制约11β-羟基类固醇脱氢酶1型（11b-HSD1）活性方面的药物应用，或用于预防和/或治疗由11β-羟基类固醇脱氢酶1型介导的各种疾病。
• Compounds
  申请人：Arora Jalaj

  公开号：US20060122397A1

  公开（公告）日：2006-06-08

  The present invention relates to new compounds of formula I, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.

  本发明涉及化合物I的新化合物，其制备过程和其中制备的新中间体，含有该化合物的制药配方以及在治疗中使用该化合物的用途。
• Pharmaceutical Composition For Preventintion And Treatment Of Restenosis Comprising Isoxazole Derivatives
  申请人：Hwang Sun Gwan

  公开号：US20110028506A1

  公开（公告）日：2011-02-03

  There is provided a pharmaceutical composition for prevention and treatment of restenosis comprising isoxazole derivatives. The pharmaceutical composition includes a therapeutic effective amount of isoxazole derivatives represented by Formula 1 or pharmaceutically available salts thereof. The pharmaceutical composition may be useful to prevent and treat vascular restenosis since the pharmaceutical composition shows an anti-restenosis activity and accelerates the re-endothelization.

  提供了一种预防和治疗再狭窄的药物组合物，包括异噁唑衍生物。该药物组合物包括一定量的异噁唑衍生物（由公式1表示）或其药学上可用的盐。该药物组合物可用于预防和治疗血管再狭窄，因为该药物组合物具有抗再狭窄活性并加速内皮再生。
• ISOXAZOLE DERIVATIVES AND USE THEREOF
  申请人：SK Biopharmaceuticals Co., Ltd.

  公开号：EP1971600B1

  公开（公告）日：2013-08-21